scPharmaceuticals Inc. (SCPH)
NASDAQ: SCPH · Real-Time Price · USD
5.63
0.00 (-0.09%)
At close: Sep 12, 2025, 4:00 PM EDT
5.63
0.00 (0.09%)
After-hours: Sep 12, 2025, 5:47 PM EDT
scPharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover scPharmaceuticals stock have a consensus rating of "Buy" and an average price target of $12, which forecasts a 113.33% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $18.
Price Target: $12 (+113.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for scPharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $6 | Strong Buy → Hold | Downgrades | $6 | +6.67% | Aug 26, 2025 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 25, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +113.33% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +220.00% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +220.00% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
75.92M
from 36.33M
Increased by 108.95%
Revenue Next Year
135.36M
from 75.92M
Increased by 78.30%
EPS This Year
-1.09
from -1.91
EPS Next Year
-0.23
from -1.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.0M | 167.4M | |||
| Avg | 75.9M | 135.4M | |||
| Low | 69.5M | 110.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.2% | 120.5% | |||
| Avg | 109.0% | 78.3% | |||
| Low | 91.2% | 45.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.08 | 0.21 | |||
| Avg | -1.09 | -0.23 | |||
| Low | -1.09 | -0.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.